Recurrent Fulminant Myocarditis Accompanied by Lymphoid Follicle Formation in Myocardium

Takashi Omatsu¹, Takaharu Hayashi¹, Yasuhiro Ichibori¹, Nobuhiko Makino¹, Akio Hirata¹, Yoshio Yasumura², Atsushi Hirayama¹ and Yoshiharu Higuchi¹

Abstract:
A 76-year-old man developed repeated fulminant myocarditis in a short period, and immunosuppressive therapy was remarkably effective. A pathologic evaluation showed that inflammatory cells had infiltrated the myocardium. Not only invasion of inflammatory cells but also the formation of lymphoid follicle was noted. Chronic myocardial inflammation was proven, but cardiac sarcoidosis was negative according to the results of various examinations. This is the first report of recurrent autoimmune myocarditis with a lymphoid follicle in the myocardium. These findings may suggest a novel pathogenesis of myocarditis.

Key words: myocarditis, recurrence, ectopic lymphoid follicles, immunosuppressive therapy

Introduction
In most cases, the etiology of myocarditis is unknown. Myocarditis can result from a wide spectrum of infectious pathogens, including viruses, bacteria, chlamydia, rickettsia, fungi, and protozoans, as well as toxic and hypersensitivity reactions (1). In Europe and North America infection with enteroviruses is thought to be the leading cause of disease, especially infection with coxsackievirus B3 (2). Non-infectious causes of myocarditis are alcohol, radiation, chemicals (hydrocarbons and arsenic), and drugs, including doxorubicin and immune checkpoint inhibitor (3).

Acute necrotizing eosinophilic myocarditis and giant-cell myocarditis are two rare idiopathic disorders that share histological features of extensive myocyte necrosis, little fibrosis in the acute phase, and eosinophil-rich infiltrates. These histological myocarditis entities are known to have a good therapeutic response to immunosuppressive agents (4).

We herein report a case of autoimmune myocarditis that did not have evidence of cardiac sarcoidosis, giant-cell myocarditis, or eosinophilic myocarditis and was accompanied by the formation of lymphoid follicles in the myocardium.

Case Report
A 76-year-old man was transported to our hospital with chief complaints of general fatigue. Echocardiography revealed a markedly impaired ventricular function. The troponin-T levels were elevated at 1.80 ng/mL, and his serum auto-immune antibody was negative (Table). His symptoms gradually worsened, and the hourly urine volume decreased despite the intravenous administration of dobutamine at 2.0 g and milrinone at 0.25 g, reaching <10 mL/h. Coronary angiography revealed that his coronary artery was intact (S. 1). We therefore inserted an intra-aortic balloon pump (IABP) to support his circulation. After insertion of the IABP, the left ventricular ejection fraction gradually recovered, and on day 7, he was successfully weaned off of the IABP. On day 24, he was discharged with New York Heart Association (NYHA) I (Fig. 1A).

Two months after discharge, he was re-admitted with a chief complaint of general fatigue. On admission, his body temperature was 36.2 °C, pulse rate was 80 bpm, and blood pressure was 69/57 mmHg. His troponin-T and CK levels were elevated at 2.79 ng/mL and 318 U/L, respectively (Table), and an electrocardiogram (ECG) showed double-bundle branch block accompanied by complete right-bundle branch block.
and left axis deviation (Fig. 2). Echocardiography revealed the marked reduction in the function of both ventricles again. He soon slipped into cardiogenic shock accompanied by complete AV block.

We performed a myocardial biopsy, supported by an IABP, temporary pacemaker and intravenous administration of an inotropic agent. A pathologic evaluation showed that inflammatory cells had infiltrated the myocardium. Biopsy specimens revealed acute lymphocytic myocarditis, showing not only invasion of inflammatory cells but also the formation of fibrosis. In addition, a lymphoid follicle was observed (Fig. 3).

Based on these findings, we immediately administered a high dose (1,000 mg/day) of intravenous glucocorticoid for 3 days. After the first high-dose steroid administration, his atrioventricular conduction recovered, and his mixed venous oxygen saturation gradually began to rise. On day 4, he was successfully weaned off of the IABP. Gallium scintillation revealed no accumulation of nuclide in the myocardium (S. 3). Following steroid pulse treatment, he received oral prednisolone, supported by an IABP, and on day 42, he was weaned from inotropic agents. Finally, on day 70, he was discharged from our hospital taking 30 mg of prednisolone a day (Fig. 1C).

### Table 1. Laboratory Findings during the Patient’s Clinical Course.

|                | first admission | second admission | before discharge | third admission |
|----------------|-----------------|------------------|------------------|----------------|
| WBC (10³/mL)   | 7200            | 7700             | 10200            | 9400           |
| Eosinophil (%) | 1.5             | 0.9              | 0.4              | 0.3            |
| Hb (g/dL)      | 10.5            | 12.5             | 15.0             | 13.3           |
| HR (bpm)       | 32              | 39.7             | 43.3             | 41.3           |
| platelets (10³/µL) | 10.6            | 11.7             | 15.5             | 9.8            |
| CK (U/L)       | 196             | 318              | 19               | 150            |
| CK-MB (U/L)    | 24              | 57               | 9                | 28             |
| AST (U/L)      | 152             | 83               | 23               | 56             |
| ALT (U/L)      | 199             | 28               | 40               | 49             |
| LDH (U/L)      | 626             | 482              | 279              | 350            |
| BUN (mg/dL)    | 20              | 16.1             | 17.5             | 21.7           |
| Cr (mg/dL)     | 0.69            | 0.96             | 0.80             | 0.85           |
| CRP (mg/dL)    | 4.13            | 4.94             | 0.01             | 5.32           |
| NT-pro BNP (pg/ml) | 14960         | 14608            | 1346             | 8425           |
| Troponin T (ng/mL) | 1.8            | 2.79             | 0.024            | 1.56           |
| ACE (U/L)      | 2.1             | 2.1              | 2.1              | 2.1            |
| Anti-nuclear antibody | negative | negative |

Immunosuppressive therapy is effective against giant-cell myocarditis, cardiac sarcoidosis, and eosinophilic myocarditis (12) but is conversely ineffective against myocarditis due to a persistent viral infection according to previous large-
Figure 1. (A, B, C): Clinical course of the patient at each admission. The left vertical axis shows mixed venous oxygen saturation (SVO₂), and the bar graph shows the total urine volume per day. A: Dobutamine was administered starting at 2 g and gradually reduced with improvement in the hemodynamics. On day 2, the intravenous administration of milrinone was started at 0.15 g and increased to 0.2 g before being gradually reduced. The left ventricular ejection fraction (LVEF) was decreased at 32% and then recovered to 54% at discharge. B: On admission, a myocardial biopsy was performed, supported by an IABP and temporary pacemaker. The intravenous administration of dobutamine was started from 3 g. On day 2, the oral administration of enalapril was started at 2.5 mg. C: Dobutamine and milrinone were started from 2 g and 0.15 g, respectively. Dobutamine was gradually increased to 5 g, and on day 4, noradrenaline was started from 0.1 g against prolonged hypotension despite IABP support.

Figure 2. The electrocardiograms recorded at each admission and discharge.
The findings of pathological specimens were compatible with autoimmune myocarditis. A: Inflammatory cells had infiltrated extensively. B: Myocardial fibrosis was occasionally found by Masson trichrome stain. C, D: Inflammatory cells formed a lymphoid follicle that indicated the persistence of chronic inflammation. D is an enlarged image of the square-dashed area of C.

Table 2. Summary of the Patient’s Clinical Course from the First Admission to the Final Discharge.

| Time                        | Events                                                                                                                                 |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| 1st admission               | He presented our hospital complaining of general fatigue, and echocardiography revealed his both ventricular function was remarkably reduced. Intra aortic balloon pumping (IABP) was inserted to support his circulation. |
| 2nd admission (two months after discharge) | He came to our hospital again because of general fatigue. He became complete AV block and soon fall into shock vital. He was treated by intravenous administration of high dose of methyl prednisolone. At this admission, he received endocardial biopsy before administration of methylprednisolone. |
| 3rd admission (eight months after discharge) | Unfortunately, his myocarditis had recurred. He could be recovered again owing to IABP and methyl prednisolone. |

Barry et al. (5) stated that causes of myocarditis could be classified into three groups: autoimmunity, toxic, and infection. Given the pathological findings showing persistent activation of acquired immunity in the myocardium and clinical features, wherein immunosuppressive therapy was remarkably effective, we ultimately diagnosed this case as autoimmune myocarditis. These histological findings were proof of acquired immunity, specifically humoral immunity, that had been activated by an auto-antigen in the myocardium. Such
specific findings are expected to help elucidate the etiology of myocarditis.

**Statement of consent**

The authors confirm that written consent for the submission and publication of this case report, including images and associated text, has been obtained from the patient in line with COPE guidance.

The authors state that they have no Conflict of Interest (COI).

**References**

1. Sagar S, Liu PP, Cooper LT Jr. Myocarditis.. Lancet 379: 738-747, 2012.
2. Feldman AM, McNamara D. Myocarditis. The New England journal of medicine 343: 1388-1398, 2000.
3. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. The New England journal of medicine 375: 1749-1755, 2016.
4. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter giant cell myocarditis study group investigators. The New England journal of medicine 336: 1860-1866, 1997.
5. Trachtenberg BH, Hare JM. Inflammatory cardiomyopathic syndromes. Circulation research 121: 803-818, 2017.
6. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr, Olsen EG, Schoen FJ. Myocarditis. A histopathologic definition and classification. The American journal of cardiovascular pathology 1: 3-14, 1987.
7. Takehana H, Inomata T, Kuwao S, Nakahata J, Sasaki T, Nishii M, Kurokawa S, Izumi T. Recurrent fulminant viral myocarditis with a short clinical course. Circulation Journal: official journal of the Japanese Circulation Society 67: 646-648, 2003.
8. Jones GW, Jones SA. Ectopic lymphoid follicles: Inducible centres for generating antigen-specific immune responses within tissues. Immunology 147: 141-151, 2016.
9. Manzo A, Bombardieri M, Humby F, Pitzalis C. Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: From inflammation to autoimmunity and tissue damage/remodeling. Immunological reviews 233: 267-285, 2010.
10. Stott DJ, Hiepe F, Hummel M, Steinhauer G, Berek C. Antigen-driven clonal proliferation of b cells within the target tissue of an autoimmune disease. The salivary glands of patients with sjogren’s syndrome. The Journal of clinical investigation 102: 938-946, 1998.
11. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Paupolo M, Reynolds R, Aloisi F. Meningeal b-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain: A Journal of Neurology 130: 1089-1104, 2007.
12. Mason JW, O’Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE. A clinical trial of immunosuppressive therapy for myocarditis. The myocarditis treatment trial investigators. The New England journal of medicine 333: 269-275, 1995.
13. Mason JW, O’Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The myocarditis treatment trial investigators. The New England journal of medicine 333: 269-275, 1995.